HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, J.M. Articles by Milano, C.A. Search for Related Content PubMed PubMed Citation Articles by Jones, J.M. Articles by Milano, C.A. Related Collections Extracorporeal circulation Molecular biology Myocardial protection

Eur J Cardiothorac Surg 2002;21:847-852
© 2002 Elsevier Science NL

Adenoviral gene transfer to the heart during cardiopulmonary bypass: effect of myocardial protection technique on transgene expression

^a Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
^b Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA

Received 15 September 2001; received in revised form 22 December 2001; accepted 30 January 2002.

* Corresponding author. Present address: Department of Cardiac Surgery, Royal Victoria Hospital, Belfast BT12 6BA, UK. Tel.: +44-2890-263000; fax: +44-2890-894918
e-mail: mark{at}jmarkjones.freeserve.co.uk

Objective: Adenoviral gene transfer to the arrested heart during cardiopulmonary bypass (CPB) is a novel method of allowing prolonged vector contact with the myocardium. In this model we investigated the importance of temperature, duration of arrest and cardioplegia on transgene expression. Methods: First-generation adenoviral vector (1x10¹² total viral particles) containing the transgene for the human ß2-adrenoceptor (Adeno-ß₂AR) or ß-galactosidase (Adeno-ßgal) was delivered to neonatal piglets via the proximal aorta, during simulated cardiac surgery, and allowed to dwell for the cross-clamp duration. Four treatment groups received Adeno-ß₂AR. Groups A (n=4) and B (n=6) underwent cold crystalloid cardioplegia arrest for 10 and 30 min, respectively, Group C (n=5) underwent warm crystalloid cardioplegia arrest for 10 min, and Group D (n=5) underwent warm fibrillatory arrest for 10 min. Group E (n=6) received Adeno-ßgal and underwent cold crystalloid cardioplegia arrest (30 min). Animals were weaned off CPB and recovered for 2 days. Receptor density was assessed in membrane fractions using radioligand binding and compared using the Mann-Whitney U-test. Results: Left ventricular transgene overexpression, as evidenced by elevated ßAR density, following Adeno-ß₂AR treatment was greatest with cold cardioplegia (Group A 588±288.8 fmol/mg; P=0.002 and Group B 520±250.9 fmol/mg; P=0.01) versus control (Group E 109±8.4 fmol/mg). Overexpression also occurred with warm cardioplegia (Group C 274±69.5 fmol/mg; P=0.05) and ventricular fibrillation (Group D 215±48.4 fmol/mg; P=0.02) versus control. Comparison of the combined cold cardioplegia groups versus those treated with warm conditions showed a trend towards increased expression with cold conditions (P=0.1). Receptor density was also significantly increased in the right ventricle of animals in Group B (165±18.1 fmol/mg; P=0.03) and Group D (181±23.4 fmol/mg; P=0.02) versus control (Group E 118±5.8 fmol/mg). Conclusions: Cold crystalloid cardioplegia is not detrimental to gene transfer in vivo. In fact, there was a trend towards increased left ventricular transgene expression when the adenoviral vector was delivered following cold versus warm cardioplegia. Shorter periods of contact with the vector may reduce transgene overexpression. Therefore, gene transfer is possible during cardiac surgery with clinically used myocardial protection techniques.

Key Words: Cardiopulmonary bypass • Gene therapy • ß-Adrenergic receptor • Myocardial protection • Surgery

This article has been cited by other articles:

				J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]

				C. R. Bridges, K. Gopal, D. E. Holt, C. Yarnall, S. Cole, R. B. Anderson, X. Yin, A. Nelson, B. W. Kozyak, Z. Wang, et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1364 - 1364. [Abstract] [Full Text] [PDF]

				J. M. Jones, J. A. Petrofski, K. H. Wilson, C. Steenbergen, W. J. Koch, and C. A. Milano {beta}2 Adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1161 - 1168. [Abstract] [Full Text] [PDF]